explore -WSS

explore

author：fashion 2025-10-02 18:05:17 - browse：5721

Daniel M. Skovronsky on stage at the 2023 STAT Summit. — Dan Skovronsky, Eli Lilly's chief scientific officer, at the 2023 STAT Summit. STAT

PHILADELPHIA — In a sense, the annual meeting of the American Heart Association wasn’t a huge one for Eli Lilly. Its biggest news was about a very early study of a drug to lower blood levels of Lp(a), a protein related to cholesterol that is mainly being watched by lipidologists and drug company analysts.

But in another way, the future of Lilly, now the biggest drug company by market capitalization, hung in the balance. Why? Because researchers were presenting data on the ability of Novo Nordisk’s obesity drug Wegovy to prevent heart attacks, strokes, and deaths in people with overweight who have established cardiovascular disease. That has big implications for the market for Lilly’s own obesity drug, Zepbound, which was approved by the Food and Drug Administration last week, and for the company’s future efforts in obesity.

STAT sat down with Lilly’s chief scientific officer, Dan Skovronsky, at the AHA meeting to talk about the obesity drugs known as GLP-1s, the new Lp(a) drug, and the company’s partnership with the gene editing firm Verve. An edited transcript of the conversation follows.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： CDC advisers recommend seasonal use of Pfizer RSV shot

Wikipedia

WSS

STAT Boddities: What happens to the brain when we get scared?

CommonSpirit Health keeps growing, even as it loses money

Senators: Long

Readout Newsletter: Amylyx, Aurinia, and IQVIA

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Medical student insurance fails on mental health care coverage

focus

explore

knowledge

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA panel to weigh approval of NurOwn, controversial ALS drug

How to save PrEP access — and even expand it

AMAs digital advisors table RPM coding reform proposal, again

Peter Hotez and the public health issue of online harassment

Lasker Awards 2023: Winners in biomedical research

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Having children helps parents live longer, especially after age 80

Medicare details structure of new drug price negotiation program

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

leisure time

Medical student insurance fails on mental health care coverage

Thermo Fisher plant for manufacturing gene therapies to expand

Hearing on Medicare drug price negotiation gets unusually heated

It's been 20 years since Dolly the sheep. Where's my clone?

Biotech lab space demand falls sharply

Thermo Fisher plant for manufacturing gene therapies to expand

explore

explore

Wikipedia

Wikipedia